Companies › Allotera Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WU-CART-007 Anti-CD7 allogeneic CAR-T cell therapy | CD7 | Phase 2 | T-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| WU-NK-101 NK cell therapy | – | Phase 1 | Colorectal Cancer Metastatic | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05674526 | WU-NK-101 | Phase 1 | Colorectal Cancer Metastatic | Oncology | Sep 2025 |
| NCT06514794 | WU-CART-007 | Phase 2 | T-cell Acute Lymphoblastic Leukemia | Oncology | Dec 2026 |
PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology
Scancell PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology Diakonos Oncology ImmVira Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.